The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1245 Weight Loss articles
Medical experts are advising Americans using weight loss medications to be aware of the impact on their travel plans during Thanksgiving. With over 33 million people estimated to be on these prescriptions, understanding necessary precautions is crucial. Key considerations include proper storage, documentation, and timing of doses.
The entertainment industry is seeing a trend of slimmer celebrities, leading to discussions about the role of medications like Ozempic. This shift raises questions about evolving beauty standards and body positivity in Hollywood.
WeightWatchers intends to offer Novo Nordisk's oral Wegovy upon potential FDA approval. This strategic move occurs amidst a competitive weight-loss drug market, aiming to provide a convenient alternative to injections. The FDA is also expediting GLP-1 treatments to improve access.
The demand for weight-loss drugs is surging. New medications promise increased effectiveness and easier administration, including oral options. Several pharmaceutical companies are developing improved injectable drugs.
Richard Saynor, CEO of Sandoz, expects biosimilars referencing semaglutide to be available in Canada in early 2026. This projection comes as Novo Nordisk's patent protection for the drug nears its end. Sandoz intends to capitalize on the commercial opportunity as soon as regulatory approval is granted.
Hair loss, or 'GLP-1 shedding,' can be a concerning side effect for those using GLP-1 drugs. However, solutions are available to effectively address this issue. A dermatologist provides insights into managing hair loss associated with these medications.
Meghan Trainor's slimmer appearance, attributed to Mounjaro, has ignited online discussions. While some celebrate her health dedication, others miss her earlier look. The debate highlights body image and societal pressures.
Novo Nordisk has reduced the price of Wegovy in India by as much as 37% to better compete with Eli Lilly's Mounjaro. This decision follows Mounjaro's rise to become the best-selling weight-loss medication in India by value.
Research comparing tirzepatide and semaglutide shows both medications reduce the risk of major cardiovascular events. The study highlights the early onset of cardioprotective effects, suggesting mechanisms beyond just weight loss. These findings support the integration of both agents into cardiovascular clinical practice.
